UK Government Must Do More to Reduce Risk of vCJD Infection
News Jul 24, 2014
More action is needed to ensure that variant Creutzfeldt-Jakob disease (vCJD), the human form of bovine spongiform encephalopathy (BSE), is not inadvertently transmitted from person-to-person through medical procedures, the Science and Technology Committee has today warned.
Andrew Miller MP, Chair of the Science and Technology Committee, commented:
"Variant CJD is a terrible disease and thankfully cases are now rare. However, research suggests that around one in 2,000 of us could be unknowingly carrying the infectious prions responsible for the condition. This raises the worrying prospect that these prions could be transmitted to others via blood transfusions and other medical procedures.
There remains significant uncertainty about the magnitude of this risk and the Government therefore claims to be taking a precautionary approach. But our inquiry has shown that its attitude towards vCJD today is far less precautionary than it was in the past. Indeed, recent policy seems to have been driven less by precaution than by economic prudence and a hope that the storm has now passed. This optimism is not supported by the available evidence."
Transmission via surgery
Contaminated surgical instruments are a potential source of ‘prion transmission’—the mechanism by which both CJD and vCJD are spread. However, evidence to the inquiry suggests that Government guidance on preventing prion transmission may not have been fully implemented across the NHS. According to figures published by Public Health England, 43 incidents occurred between January 2010 and March 2013 in which surgical patients may have been exposed to CJD as a result of infection control guidance not being properly followed, for example because the infected patient was not diagnosed with CJD at the time that they underwent surgery. The Committee says that Ministers must work with the National Institute of Health and Care Excellence (NICE) and the Advisory Committee on Dangerous Pathogens to assess the extent to which precautions are being taken in hospitals and come up with a plan to improve implementation if preliminary findings prove that compliance is unsatisfactory. The Committee also recommends greater support for technologies potentially capable of more effectively decontaminating surgical instruments.
Andrew Miller MP:
"Prions bind strongly to metal surfaces and the Government acknowledges that standard decontamination treatments are ineffective in removing prions from surgical instruments.
It is known that CJD can be transmitted through the use of contaminated surgical instruments but the Government's response to this threat has been insufficient. It has failed to support development of a technology capable of eliminating this risk and instead chooses to rely on guidance which it knows is only partially effective. And evidence suggests that this guidance is not even followed in some parts of the NHS."
Transmission via blood transfusion
Evidence presented to the inquiry suggests that we cannot be confident that prions are not present in the blood supply. To date, there have only been four confirmed cases in which vCJD is known to have been transmitted via blood transfusion. All of the implicated transfusions are thought to have occurred in the 1990s; however, concerns were raised during the inquiry that asymptomatic prion transmission could still be widespread and could potentially lead to further cases of transfusion-transmitted vCJD in the future.
Andrew Miller MP:
"We know that vCJD can be transmitted via blood transfusion because it has happened in the past. And we have reason to believe that prions may still be present in the blood supply, so there is a chance that it could happen again. However, in the absence of a reliable vCJD blood screening test, we are unable to discard those donations that might be dangerous.
In our view, the Government could be doing more to help mitigate this risk of infection. Key steps would be for it to reduce uncertainty by supporting relevant research, for example by using the prototype blood test developed by the MRC prion unit in a large-scale study to better understand the rate of ‘silent infection’ across the UK donor pool. The Minister stressed that a lot of public money had already gone into the development of this test and she appeared reluctant to commit more. But the money already invested is a sunk cost and to cut off support now, when the task appears to be nearing completion, would be a false economy."
In the vast majority of cases the benefits of receiving a transfusion will far outweigh the risk of acquiring a transfusion-transmitted infection. However, the Committee is warning against complacency and is urging UK Blood Services to remain vigilant to the threat posed by vCJD, as well as other blood-borne pathogens such as emerging viruses. In the past it has often taken multiple cases of infection before threats have been recognised and mitigated.
The report recommends that the Government commission a full assessment of the risks currently faced by the UK blood supply so that knowledge gaps can be filled and additional risk reduction measures and technologies developed as appropriate.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE